i-Pharm GxP

At i-Pharm GXP, our consultants collaborate closely with clients to deliver services uniquely tailored to their specific requirements. Check out the slides below to learn more about our approach to project delivery and how we bring this service to life. ⬇️ If you’re looking to scope a project, feel free to connect with our team or visit our website: 🔗 https://lnkd.in/dS9x-f6K #projectdelivery #consultancy #iPharmGxP

Following our recent post about the novel nickel-based catalyst developed by researchers at Ohio State University, we want to hear your thoughts on its practical applications in drug development. This catalyst enhances the efficiency and stability of cross-coupling reactions, which are essential for synthesising complex drug molecules. How do you think this new catalyst will affect drug development? 🤔 ______________ Vote in the poll below and leave any further thoughts in the comments! 💬 #iPharmGxP #drugdiscovery #lifesciences

i-Pharm Consulting have released their November edition of i-Pharm Insights, where they're looking at the emerging reserach into cancer vaccines and what this can mean for future treatment. Check out the full article here: 🔗 https://lnkd.in/ed9rBwum #iPharmInsights #iPharmGxP #cancertreatment

Researchers at Ohio State University have developed a novel nickel-based catalyst that enhances the efficiency and stability of cross-coupling reactions, crucial for synthesising complex three-dimensional drug molecules. This innovation offers a cost-effective alternative to traditional palladium catalysts. By facilitating the reliable assembly of diverse molecular structures, this catalyst opens new avenues in pharmaceutical research, potentially leading to more effective therapies. __________ How do you envision this breakthrough impacting future drug development? Share your thoughts in the comments. 💬 #iPharmGxP #drugdiscovery #lifesciences

Meeting evolving regulatory expectations while balancing project timelines involves quality assurance, complex validation protocols or keeping up with AI-driven innovations. 🤖 For many in the life sciences and biologics industries, the challenge often lies in finding the right balance between maintaining compliance and moving forward with innovation. With regulations and technology constantly shifting, it’s understandable that businesses are seeking smarter ways to stay ahead. We focus on delivering practical, quality-driven solutions that help our clients and candidates achieve their project goals without compromising compliance. ______________ Click on the link to learn more about our capabilities: 🔗 https://lnkd.in/efB4GTZE #iPharmGxP #compliance #qualityassurance

As today is Veterans Day, we’re taking a moment to appreciate the extraordinary contributions of those who have served. 🇺🇸 From their courage and commitment to their resilience and leadership, veterans inspire us in countless ways. From everyone at i-Pharm GxP, Happy Veterans Day! #VeteransDay #iPharmGxP

Last week, we conducted a poll to gauge your opinions on the most significant trends impacting aseptic processing over the next few years. 📊 The results were telling! An overwhelming 67% of you believe that AI and digital production will be the driving force in this field, while 17% pointed to tighter regulatory compliance and another 17% emphasised the importance of sustainability initiatives. This strong inclination towards AI and digital solutions highlights a huge shift in the industry. ____________ We’d love to hear what you think about these findings. Share your thoughts in the comments below! 💭 #AsepticProcessing #AI #iPharmGxP

As we look towards 2025, the FDA is making its priorities clear: LDTs, AI in medical devices and cybersecurity are at the top of their agenda. 🏢📝 The Center for Devices and Radiological Health plans to finalise new guidance on LDT regulations, with a strong focus on enforcement discretion policies. This move is a signal to laboratories and medtech companies to ensure they’re aligned with changing standards. Guidance on AI lifecycle management and cybersecurity in premarket submissions is set to be finalised, creating new expectations for medical device developers. _____________ Read more on the CDRH Guidelines here: 🔗 https://lnkd.in/e4Xukz9q #iPharmGxP #FDA #AI

GS-CHO cell lines are evolving to power next-gen therapies like bi-specific antibodies and complex recombinant proteins. These innovations are game-changers for tackling autoimmune diseases, cancer and neurodegenerative conditions. 🧬 Why does this matter? 🤔 As our global population ages, demand for cutting-edge treatments is skyrocketing. Thanks to enhanced cell lines, data-driven bioprocesses and breakthroughs in genetic engineering, the industry is ready to deliver broader, more effective therapies. But, with this comes the need for stronger manufacturing capacity and top-notch quality control. How will these advancements shape the future of treating complex diseases? Drop your thoughts in the comments! 💭 #biologics #biopharmaceutical #iPharmGxP

In light of the recent growth in the global aseptic processing market, expected to hit $133.2 billion by 2030, it's clear that the industry is evolving rapidly. 🌍 Automation and data-driven quality control are already reshaping the field, helping manufacturers stay compliant, boost efficiency and ensure product safety. But what will shape the industry next? As we approach 2025, we want to hear your thoughts. What do you think will be the most significant trend impacting aseptic processing over the next few years? _______________ Vote below and share your thoughts in the comments! 💬 #iPharmGxP #asepticprocessing #lifesciences